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Abstract
The secreted semaphorin Sema3E controls cell migration and invasiveness in cancer cells.
Sema3E-receptor, PlexinD1, is frequently upregulated in melanoma, breast, colon, ovarian
and prostate cancers; however, the mechanisms underlying PlexinD1 upregulation and the
downstream events elicited in tumor cells are still unclear. Here we show that the canonical
RBPjk-dependent Notch signaling cascade controls PlexinD1 expression in primary endo-
thelial and cancer cells. Transcriptional activation was studied by quantitative PCR and pro-
moter activity reporter assays. We found that Notch ligands and constitutively activated
intracellular forms of Notch receptors upregulated PlexinD1 expression; conversely RNAi-
based knock-down, or pharmacological inhibition of Notch signaling by gamma-secretase
inhibitors, downregulated PlexinD1 levels. Notably, both Notch1 and Notch3 expression
positively correlates with PlexinD1 levels in prostate cancer, as well as in other tumor
types. In prostate cancer cells, Sema3E-PlexinD1 axis was previously reported to regulate
migration; however, implicated mechanisms were not elucidated. Here we show that in
these cells PlexinD1 activity induces the expression of the transcription factor Slug, down-
regulates E-cadherin levels and enhances cell migration. Moreover, our mechanistic data
identify PlexinD1 as a pivotal mediator of this signaling axis downstream of Notch in pros-
tate cancer cells. In fact, on one hand, PlexinD1 is required to mediate cell migration and E-
cadherin regulation elicited by Notch. On the other hand, PlexinD1 upregulation is sufficient
to induce prostate cancer cell migration and metastatic potential in mice, leading to func-
tional rescue in the absence of Notch. In sum, our work identifies PlexinD1 as a novel tran-
scriptional target induced by Notch signaling, and reveals its role promoting prostate
cancer cell migration and downregulating E-cadherin levels in Slug-dependent manner.
Collectively, these findings suggest that Notch-PlexinD1 signaling axis may be targeted to
impair prostate cancer cell invasiveness and metastasis.
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Background
Plexins are cell surface receptors for extracellular signals of the semaphorin family[1]. Mam-
malian semaphorin genes are divided into five classes—Class 3 to 7, which bind directly to
Plexins or in association with co-receptor molecules. Semaphorin signaling has been impli-
cated in a wide range of functions in development and in disease, ranging from axon guidance
duringmorphogenesis to cancer progression [2]. Semaphorin signaling has been found to reg-
ulate multiple hallmarks of cancer such as invasion, angiogenesis, and proliferation among oth-
ers [3]. Depending on the context of available signaling intermediates, they are found to play
either a tumor suppressive or a pro-tumorigenic role. For instance, in endothelial cells Sema3E
and its specific receptor PlexinD1 inhibit cell-substrate adhesion [4] and exert an anti-angio-
genic function, while in cancer cells they have been shown to have a pro-tumorigenic role [5].
In particular, Sema3E and its mature isoform Sema3E-p61 regulate migration and invasion of
melanoma, colon, lung, and ovarian cancer cells, and Sema3E-PlexinD1 signaling was reported
to promote invasive/metastatic phenotype [5,6]. We reported previously that in certain cancer
cells Sema3E-PlexinD1 can transactivate ErbB2 signaling, promoting the invasive/metastatic
phenotype [5]. Other studies showed Sema3E-dependent activation and nuclear translocation
of the transcription factor Snail in ovarian cancer cells [6], or rather dependence-receptor fea-
tures of PlexinD1 in breast cancer cells [7].
Notably, PlexinD1 is expressed at low levels in adult tissues, but it is typically overexpressed
in multiple types of human cancer [5,6,7,8,9], both in tumor cells and in tumor vasculature; yet,
the mechanisms sustaining this expression have not been elucidated. PlexinD1 is also remark-
ably expressed in endothelial cells, where it is required for vascular patterning in angiogenesis
[10]. Recently, it was reported that VEGF positively controls the expression of PlexinD1 in
endothelial cells of actively sprouting blood vessels in retinal development [11]. Moreover, Plex-
inD1 expression was induced by hypoxia in post-ischemic regenerating vessels [12]. However,
the relevance of this pathway in other tissues has not been investigated. Notably, in the vascula-
ture of developing retina Notch signalingwas associated in one study with reduced PlexinD1
expression [11], while in a different developmental system this was not confirmed [13]. There
are four knownNotch receptors (Notch1—Notch4); upon binding of ligands of the DSL family
—Jag1, Jag2, Dll1, Dll3, Dll4—Notch receptors undergo subsequent cleavage by TACE and
gamma secretase.Once released in the cytosol, Notch intracellular domain (N-ICD) translocates
into the nucleus, where it forms complex with RBPjk/CBF1 transcription factor to regulate gene
transcription. Notch family members are overexpressed in several human tumors, and their sig-
naling cascade is often activated by an increased load of notch ligands in the tumor microenvi-
ronment, for example in response to inflammation or hypoxia [14,15].
Sema3E-PlexinD1 signaling was recently reported to be upregulated in prostate cancer and
regulate cell migration [8]. Prostate cancer is one of the most frequently diagnosed cancers in
men.While relatively tractable in its early stage, in the advanced stage this cancer has a poor
prognosis due to regional invasion and metastatic dissemination. The implicated mechanisms
are under intense investigation. Similar to other tumors, in prostate cancer, Sema3E was found
to be expressed at higher levels compared to normal tissue; PlexinD1 staining too was found to
be higher in tumors compared to benign tissue [8]. It was further observed that the cleaved
form of Sema3E, Sema3E-p61, was expressed in prostate cancer cell lines. However, the mecha-
nisms regulating cell migration downstream of PlexinD1 in this system are still unclear. On a
separate note, Notch signaling ligand—Jag1—has been independently reported to be a marker
of poor prostate cancer progression [16]. Consistently, Jagged1-Notch1 signaling has been
shown to regulate migration and invasion of prostate cancer cells via the activation of Akt,
mTOR and NF-kB signaling pathways [17].
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Here we report that the expression of Sema3E-receptor PlexinD1 is under control of the
Notch pathway, which is commonly activated in tumors and associated with malignant pro-
gression. PlexinD1 regulation occurs at the promoter level, through the canonical Notch signal-
ing pathway mediated by RBPjk/CBF1 transcription factor. Notch signaling cascade has been
found to promote cancer metastasis via transcriptional programs regulating cell-cell contact
and cell migration [18,19]. Here we show that the upregulation of Notch-target PlexinD1 in
prostate cancer cells upholds Slug expression and downregulates E-cadherin levels, a program
associated with cell migration, epithelial—to—mesenchymal transition and metastasis.
Materials and Methods
Cell lines and chemicals
Tumor cell lines were obtained from ATCC and cultured in a humidified incubator with 5%
CO2 at 37°C in media supplemented with 10% FBS, penicillin and streptomycin. U87MG,
U251, A549 were cultured in DMEM; PC3 and DU145 were cultured in RPMI; SKOV3 was
cultured in McCoy media; HUVECwere cultured in EGM-2 media containing growth factors
(Clonetics), 100 IU/ml of penicillinG sodium and 100ug/ml of streptomycin sulfate. Cell treat-
ments with gamma secretase inhibitors DAPT (Sigma, D5942-5MG; used 25μM) and
RO4929097 (Selleckchem, S1575; used 25μM) were done for 72 hours in media supplemented
with 10% FBS. Cell treatments with LY294002 (10μM) and PD98059 (10μM) were done for 24
hours in media supplemented with 10% FBS.
Gene transfer and RNA interference in mammalian cells
Stable cDNA and shRNA expression in mammalian cells was achieved by means of lentiviral
vectors, as previously described [20]. Briefly, calcium phosphate method was used to co-trans-
fect transfer plasmids, packaging vectors and constructs expressing VSV-G envelope protein in
293T cells. Tumor cells were transduced by incubation with lentiviral vector suspensions, in
the presence of 8μg/ml polybrene, for 8–12 hours. In other experiments, cDNA and siRNA-
expressing constructs were transiently transfectedwith Lipofectamine 2000 (Life Technologies)
according to manufacturer’s instructions.
siRNA, shRNA and DNA constructs
Notch1 downregulation was achieved by lentiviral-mediated stable expression of (puromycin
selectable) shRNA expression constructs: TRCN0000350330, TRCN0000003359 or
TRCN0000003362 (indicated as shNotch1_2, shNotch1_3, and shNotch1_5, respectively in
the validation experiment shown in S3C Fig); the latter construct was also simply indicated as
shNotch1 in experiments throughout the manuscript. PlexinD1 downregulation was achieved
by (puromycin selectable) lentiviral-mediated stable expression of shRNA TRCN0000061548
(#48; mainly used in this study and usually dubbed as “shPlexinD1” in the manuscript) and
TRCN0000061552 (#52); or by transfection of siRNAs targeting the 3’-UTR sequence of
PLXND1 transcript:GCUACUUGAUCUUGCUGAA. Sema3E knock down was
achievedby stable expressionof shSema3Esequence:GGTTACGCCTGTCA
CATAA [5]. Lentiviral vectors were also used to transfer stable expression of VSV-G tagged
PlexinD1 (simply dubbed as “PlexinD1” in the manuscript), as previously shown [5]. Consti-
tutively active intracellular domains of Notch1 and Notch3 (N-ICD), or truncated Notch1-ΔE
construct [21] (a gift from Claudio Talora and Isabella Screpanti, Rome) were overexpressed
by transient transfection.Mouse Jag1 Fc and Dll1 Fc cloned in pTracer CMV vectors [22]
were gifts from Takayasu Kato. Hes1-Luc reporter construct, cloned in pGL2 [23] was a gift
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from Alain Israel, France. 12XCBF/12XCSL-DsRedExpressDR reporter construct was a gift
from Federico Bussolino and Urban Lendhal [24]. Slug (SNAI2 gene) silencing was achieved
by transfection of siRNA sequence: 50- CAAUAAGACCUAUUCAACU -3 [25].
Luciferase reporter assays
Luciferase reporter assays were done with Hes1 promoter driving firefly luciferase or with a
1567bp region of PlexinD1 promoter (from 1388bp upstream of TSS to 179bp downstream of
it) (Genecopoeia)driving secretable Gaussia luciferase. Cells were transfected using lipofecta-
mine 2000 with 1ug of reporter construct in combination with 10-100ng of Notch1-intracellu-
lar domain (N1-ICD), N3-ICD, RBPjk1, or DN-RBPjk expressing constructs; a GFP-
expressing plasmid was added in all conditions, for internal normalization purposes. 48hrs
after transfection, cells were lysed and luciferase assays conducted using luciferase assay system
(Promega, Madison,WI, USA). For Hes1-Luc assay, Promega luciferase assay system was used;
for PlexinD1-Luc assay, Secrete-Pair Gaussia Luciferase assay system (Genecopoeia)was used.
Two mutants of PlexinD1 Gaussia Luc reporter were generated using restriction site-based
deletion:Mut1_D1 was deleted between EcoR1 and AfeI sites in the promoter sequence, while
Mut2_D1 derived from deletion of the sequence comprised between two NheI sites (both con-
structs were verified by sequencing).
Transwell migration assays
Transwell migration assays were performed using Transwell1 chamber inserts (Costar, Cam-
bridge, MA) with a porous polycarbonate membrane (8 μM pore size; CorningCostar Incorpo-
rated, NY, USA). Briefly, the lower side of the filter was coated with 10 μg/ml fibronectin and
blocked with 1% BSA. Approximately 5x104 cells were added in the upper chamber, and
allowed to migrate through the filter towards the lower chamber containing the indicated fac-
tors. In parallel, the equal number of cells were seeded in cell culture multiwell plates to check
for equal cell loading. After 24hrs non-migrated cells from the upper side were removed by a
cotton swab, followed by fixing of cells with 11% Glutaraldehyde and staining with crystal vio-
let. Microscopic images were then quantified either by cell counting or by converting to a
binary image and quantifying the integrated pixel values using ImageJ (NIH). Experiments
were repeated at least twice in replicates, showing consistent results.
Fluorescence labeling of living cells
Fluorescent labeling of cells was done using Vybrant DiD cell labeling solution (Molecular
Probes). Cells were washed with PBS and incubated with 10μM Vybrant DiD in 10% FBS
RPMImedia for 30 mins, allowing the cells to get labelled. Cells were then trypsinized, centri-
fuged and washed twice with PBS. Cells were then counted and suspended in PBS and used in
extravasation assay. 1 million cells were used per mice.
Wound healing assay
Wound healing assay was performed in confluent monolayer of cells grown in 6-well plates. A
pipette tip was used to make three scratches in cell monolayers; cells were washed twice and
images were taken at starting time point, followed by incubation in appropriate media. Later
images were taken after 24 hrs, images were aligned and analyzed to score for wound closure
(based on measurement of residual wound area). In the case of DAPT and RO4929097 treat-
ments, cells were pre-incubated with the drugs for 48hrs.
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Real time quantitative PCR analysis of gene expression
Total RNA from tumor cell lines was isolated using RNeasy Protect Mini kit (Qiagen) according
to the manufacturer's instructions. cDNA preparation was performed according to standard
procedures, usingM-MLV Reverse Transcriptase (Promega) and oligo-dT primers / random
hexamers. PCR was performedby applying Taqman probes (Applied biosystems): PlexinD1
(Hs00391129_m1, Applied biosystems), Notch1 (Hs01062014_m1), Hes1 (Hs00172878_m1),
beta actin (Hs99999903_m1). Alternatively, PCR was conducted with SYBR GreenMaster Mix
(Life Technologies) and run in Applied Biosystems 7900HT Fast Real-Time PCR system, by
applying the following primer pairs: PlexinD1(Fwd—ACCGAGCAGTGGATGATTCT, Rev—
TCCTGGTGAACGACACAGAC), GAPDH (Fwd—GAAGGTGAAGGTCGGAGTC, Rev—GAA
GATGGTGATGGGATTTC),PlexinB1(Fwd—CACTGAACCCCACACCTTTC, Rev—
ATAGCCACCACCTCCTCCTT), Snail (Fwd—GACTACCGCTGCTCCATTCCA,Rev—
TCCTCTTCATCACTAATGGGGCTTT),Zeb2 (Fwd—TTCCATTGCTGTGGGCCT, Rev—
TTGTGGGAGGGTTACTGTTGG), Slug (Fwd—AGATGCATATTCGGACCCAC, Rev—
CCTCATGTTTGTGCAGGAGA), Zeb1 (Fwd—AGCAGTGAAAGAGAAGGGAATGC,Rev—
GGTCCTCTTCAGGTGCCTCAG), Twist1 (Fwd—TGTCCGCGTCCCACTAGC, Rev—
TGTCCATTTTCTCCTTCTCTGG).
Metastatic cell extravasation assay
Metastatic tumor cells were labelled in culture by incubationwith Vybrant DiD (Life Technolo-
gies), according to manufacturer’s specification.One million fluorescent-labelledPC3 cells
were then injected into the lateral tail vein of 6–8 weeks old NOD/SCIDmice (Charles River
Laboratory); experimental groups included 5 animals each. The mice were sacrificed 48 hours
after injection, and quantification of metastatic cells in the lungs was done by fluorescence
microscopy by analyzing at least four independent microscopic fields per lung, using ImageJ
software (NIH) to measure signal intensity. Mice were housed in individual ventilated cages.
Animal handling was performed according to international guidelines for animal experimenta-
tion and the specific Italian Legislative Decrees no. 116 (27 Jan 1992) and no. 26 (4 Mar 2014).
This research project and relative experimental protocols have been approved by the Ethical
Committee of the University of Torino and the Ethical Committee for Animal Experimenta-
tion at the Institute for Cancer Research and Treatment IRCCS-Candiolo and by the Italian
Ministry of Health.
Protein analysis
Total cell lysates were prepared in a Tris pH 6.8–10% SDS solution (1:1) by heating at 95° for
20 mins. Protein concentration was measured using Pierce BCA protein assay kit as per the
company instructions. For western blotting 10–40 ug of protein was resolved on 7.5% or 10%
mini gels from Biorad, transferred to nitrocellulosemembrane using semi-drymethod and
immunoblotted. 10% BSA was used for filter blocking in all conditions.
The following primary antibodies were used: against Notch1, Slug and Actin (Santa Cruz
Biotechnology), against PlexinD1 (R&D Systems), against Vinculin (Sigma), against Notch3
(Cell Signaling technology), against E-cadherin (BD Transduction laboratories).
Dataset analysis
The portal assembled by the www.cbioportal.org [26] was used to analyze the correlation of
expression of PlexinD1 with Notch signaling genes.We elaborated correlation graphs of pros-
tate adenocarcinoma, colon and rectum adenocarcinoma, thyroid carcinoma, kidney renal
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clear cell carcinoma TCGA datasets (provisional); mRNA expression z-score threshold was set
at +/- 2 fold, and the category of ‘All tumors’ was chosen with input of PLXND1,NOTCH1,
NOTCH3 and SNAI2. Plots of correlation were generated under the heading of 'Plots' —> 'two
genes'. The heading of 'Mutual exclusivity' gave the p values, while the input of individual
genes yielded the spearman correlation coefficient under the heading 'co-expression'. GEO—
GSE54460 prostate cancer cell dataset was also analyzed for correlation between SNAI2 and
PLXND1 genes, while multiple genes expression fold change (vs. control) were analyzed in
GEO-GSE40403 endothelial cell dataset, upon Jag1 overexpression or Notch1 knock down.
Statistical analysis
All in vitro and in vivo experiments were performed at least two-three times. Representative
results of qPCR experiments are shown. T-test was used to assess statistical significance, indi-
cated in graphs as follows:  (p<0.001),  (p<0.01),  (p0.05).
Results
PlexinD1 is a novel transcriptional target of Notch signaling
PlexinD1 overexpression in high-grade vs. normal tissues or low-grade human tumors has
been reported in a number of studies [5,6,8]. Previous data suggested that PlexinD1may be
induced in the vasculature in response to hypoxia or Vascular Endothelial Growth Factor
(VEGF) [11,12], conditions which are also known to regulate cancer cells. In preliminary
experiments we found that VEGF significantly induced PLXND1mRNA expression in endo-
thelial HUVEC cells, but not in a range of human carcinoma cells; moreover, we also failed to
observe any significant upregulation of PlexinD1 levels in cancer cell lines exposed to low oxy-
gen tensions (data not shown). These data suggested that PlexinD1 expression in tumor cells
may be regulated by mechanisms different from those observed in endothelial cells.
Interestingly, by data mining in gene expression datasets, we found that—among other
genes–PLXND1 levels were induced almost 4-fold upon constitutive Notch1 activation in glio-
blastoma stem cells [27]. Initially, we validated these raw data in two glioblastoma cell lines—
U87MG and U251. Indeed, upon overexpressing a constitutively activated form of Notch1
(N1-ICD) we observed an appreciable increase of PlexinD1 protein levels (S1A and S1B Fig).
These findings in glioblastoma cell lines encouraged us to further study this novel regulatory
mechanism in other cell types. Constitutive Notch signaling established by transfection of
N1-ICD or a ligand-independent activatable receptor (Notch1—ΔE ICD [28]), significantly
induced endogenous PlexinD1mRNA and protein levels in 293T cells (Fig 1A and 1C). In
other experiments, we analyzed HUVEC endothelial cells, which abundantly express PlexinD1
in basal conditions, and subjected them to stable Notch1 knock down by shRNAs or blunted
its signaling cascade with the gamma secretase inhibitor DAPT [29]. In either case, interfering
with the Notch pathway led to concomitant PlexinD1 downregulation at mRNA and protein
level (Fig 1D and 1F); conversely, NICD overexpression further induced PlexinD1 levels (S1C
Fig). These data are consistent with genome-wide expression analysis in endothelial cells (GEO
Dataset—GSE40403) upon overexpression of the Notch ligand Jagged1 (S1D Fig) or Notch1
gene silencing (S1E Fig), as in either case PlexinD1 levels were concordantly regulated with
those of Notch transcriptional targets HES1 and HEY1. Together, these data supported the
conclusion that Notch signaling can positively regulate PlexinD1mRNA and protein expres-
sion in normal and tumor cells.
Prompted by these findings, we analyzed the TCGA dataset of different human cancers to
search any potential correlation between PlexinD1 expression and that of Notch family mem-
bers. To this end, we determined the correlation in the expression of PlexinD1 with Notch1
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and Notch3 in datasets of prostate, colon, thyroid and kidney cancers. As shown in S2A Fig,
PlexinD1 showed a positive Spearman correlation coefficientwith Notch1 levels, ranging from
0.43 (prostate cancer) to 0.75 (kidney renal clear cell carcinoma). Notably, Notch signaling is
implicated in the invasiveness of prostate carcinoma cells, and its expression correlates with
tumor grade [30]; moreover, Blanc et al. independently reported that PlexinD1 is upregulated
in prostate cancer [8].
Another Notch family receptor, Notch3, displayed significant positive Spearman correlation
with PlexinD1 in different tumor types (S2B Fig). As expected, the constitutively active intra-
cellular domains of both genes were similarly capable of activating the transcription of known
target genes (S2C and S2D Fig). Notably, constitutively active Notch3-ICD also upregulated
PlexinD1 levels (Fig 1G and 1H), as seen for N1-ICD. Moreover, both Notch1 and Notch3
induced PlexinD1 expression in two prostate cancer cell lines PC3 and DU145 (Fig 1I, 1J and
1K) and in U87MG (data not shown). Altogether, our data strongly indicated that Notch sig-
naling is sufficient and required to upregulate PlexinD1 expression in different cellular models.
Fig 1. PlexinD1 is a putative Notch signaling target. (A, B) HEK-293T cells were transiently transfected with a
constitutively activated Notch-intracellular domain construct (N1-ICD) or with GFP expressing construct. PlexinD1 mRNA
levels were measured by qPCR after 72 hrs (A), and protein lysates were analyzed by immunoblotting for PlexinD1 and
vinculin (B). (C) HEK-293T cells were transiently transfected with Notch1 ΔE-ICD and cell lysates were immunoblotted for
PlexinD1 and vinculin, as above. (D, E) HUVEC endothelial cells were transduced to stably express Notch1-targeted
shRNAs (shNotch1); mRNA levels were analyzed by qPCR (D), and protein lysates by immunoblotting (E; relative PlexinD1
band intensity to vinculin levels was quantified and normalized to controls), as above. (F) HUVEC cells were treated with
gamma-secretase inhibitor DAPT (25μM) to block Notch signaling, or DMSO (vehicle), for 72 hrs; lysates were analyzed by
immunoblotting for PlexinD1 and vinculin (relative PlexinD1 band intensity to vinculin levels was quantified and normalized to
controls). (G, H) HEK-293T cells were transiently transfected with activated Notch3 intracellular domain (N3-ICD); after
72hrs, mRNA levels (G) and protein lysates (H) were analyzed, as above. (I, J) PC3 prostate cancer cells transiently
transfected with N1-ICD or N3-ICD were analyzed for expression of PlexinD1 by qPCR (I) or western blotting (J). (K) DU145
prostate cancer cells transiently transfected with N1-ICD and N3-ICD were analyzed by immunoblotting for PlexinD1 and
vinculin, as above. Mean values ± SD are shown in all graphs; relative gene expression levels were normalized to controls.
doi:10.1371/journal.pone.0164660.g001
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Notch regulates PLXND1 gene promoter via the canonical RBPjk-
dependent pathway
Transcriptional gene regulation by Notch family members may bemediated by a so-called
canonical pathway, dependent on the association of nuclear-translocated NICD fragment with
the DNA-binding transcriptional effectormolecule RBPjk/CBF1, or by alternative non-canoni-
cal pathways [31]. Notably, bioinformatic analysis revealed the presence of a putative RBPjk
binding site in PlexinD1 promoter sequence (Fig 2A). Thus, we assayed whether Notch1 sig-
naling could control PLXND1 gene promoter activity by using a reporter construct containing
a 1567 bp region upstream PLXND1 transcription start site and driving the expression of secre-
table Gaussia luciferase (shown in Fig 2A). We co-transfected the reporter construct in associa-
tion with increasing amounts of N1-ICD, and found that Notch1 signaling enhanced PLXND1
promoter activity in a dose dependent manner (Fig 2B). In the same experimental setting, con-
stitutive active Notch-3 also elicited similar effects as Notch-1 (Fig 2C), confirming that both
receptors can regulate PLXND1 promoter activity.
In order to validate the relevance of the putative RBPjk binding site in PLXND1 promoter,
we assayed two truncated reporter constructs lacking this sequence (sketched in Fig 2A), and
found that they were insensitive to transcriptional regulation by N1-ICD (Fig 2D). Further
consistent with these data, upon ectopic expression of RBPjk transcriptional effector in cells we
observed a significant increase in endogenous PlexinD1 levels (Fig 2E), and enhanced PLXND1
promoter activity was observed in a reporter assay (Fig 2F). In contrast, a dominant negative
form of RBPjk that associates with NICD but it is unable to bind DNA (DN-RBPjk [32]) signif-
icantly reduced basal PLXND1 promoter activity (Fig 2F), leading to the conclusion that Plex-
inD1 expression is upregulated by the association of Notch-ICD with its transcriptional
effector RBPjk.
Notch signaling is responsible for sustaining PlexinD1 expression in
cancer cells
In order to know if Notch-dependent regulation of PlexinD1 widely occurs in cancer cells, we
stably knocked-downNotch1 expression by shRNA in a range of cell lines derived from colon
(KM-20, COLO741), prostate (PC3), lung cancer (A549) and melanoma (MDA435), and con-
sistently observedPlexinD1 downregulation (S3A Fig). Of note, we observed that the regula-
tion of PlexinD1 was specific, as Notch-targeting shRNAs did not affect the expression of
another plexin family member implicated in cancer progression—PlexinB1 (S3B Fig). Notch1
signaling appeared to be particularly relevant in regulating PlexinD1mRNA levels in prostate
cancer cells PC3 and DU145, and this was confirmed at the protein level (Fig 3A and 3B).
Importantly, we identified three independent shRNA sequences that could efficiently silence
PlexinD1 expression in prostate cancer cells (S3C Fig), and found that all of them caused con-
comitant downregulation of PlexinD1 levels, clearly suggesting a mechanistic link. Notch sig-
naling is basally present in normal and tumor cells, mainly due to autocrine/juxtacrine ligand
activity. Inhibitors of gamma-secretases are widely used reversible inhibitors that achieve a
compound inhibition of all Notch family members; these drugs include DAPT [29] and
RO4929097 [33], which is also under assessment in clinical trials.We confirmed that these
drugs could efficiently inhibit Notch signaling in different cell types carrying basal activation of
the endogenousmolecules, demonstrated by the presence of the intracellular cleaved domain
(S4A Fig). Notably, we found that 72-hour treatment with Notch inhibitors is sufficient to
downregulate PlexinD1 levels both in endothelial and in prostate cancer cells (S4B and S4D
Fig). Moreover, the treatment with DAPT or RO4929097 inhibited PLXND1 promoter activity
in PC3 and DU145 cells (Fig 3C and 3D). Further experiments demonstrated that Notch
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inhibitors can downregulate PlexinD1 expression in additional cancer cells of different histo-
type (S4E Fig). These data establish the concept that PlexinD1 expression is under control of
Notch signaling in prostate cancer cells, as well as in other tumor cell types.
Notch signaling is activated in response to different members of the Notch-ligand family.
For instance, the membrane-bound ligand Jag1 is overexpressed in human tumors and has
been linked to metastasis [16]. Thus we tested the activity of a Jag-derived soluble peptide capa-
ble of activating Notch signaling in cellular models [34]. Interestingly, Jag1 peptide could simi-
larly induce the expression of the canonical Notch target Hes1, as well as that of PlexinD1 in
PC3 cells (S5A Fig). Also, PlexinD1 promoter reporter activity was upregulated by Jag1 pep-
tide, while it was completely blunted by the combined treatment with gamma secretase inhibi-
tor RO4929097 (S5B Fig). In another set of experiments, we transiently overexpressed either
Fig 2. Notch signaling upregulates PlexinD1 promoter activity. (A) Schematic of the reporter construct pEZX-PGO2, containing a
1567 bp region from PLXND1 gene promoter (position 1 being transcription start) fused to Gaussia luciferase reporter cassette, and of
two mutant constructs with deletions of RBPjk binding site (positioned at -1382 bp upstream transcription start). (B) PLXND1 promoter-
induced Gaussia luciferase activity was revealed in cell-conditioned media of 293T cells co-transfected with mock plasmid, or with
N1-ICD (indicated amounts), in combination with the reporter construct. (C) 293T cells were transiently co-transfected with either mock
plasmid, N1-ICD or N3-ICD in combination with PlexinD1 promoter reporter construct. (D) Luciferase reporter activity was tested in 293T
cells transiently transfected with N1-ICD (or mock), in association with PLXND1 promoter region (Long D1) or with mutated promoter
constructs lacking RBPjk binding sites (Mut1_D1 and Mut2_D1, described in panel (A). (E) 293T cells were transiently transfected with
the indicated amounts of RBPjk cDNA; cell lysates were analyzed by immunoblotting for PlexinD1 and vinculin; relative band intensity
was quantified and normalized to control. (F) 293T cells were transiently co-transfected with wild-type RBPjk or dominant-negative
RBPjk (or mock) in combination with PLXND1 promoter reporter construct, and luciferase activity was revealed in cell-conditioned
media, as in (B). Bar graphs indicate mean values (normalized to controls) ± normalized SD.
doi:10.1371/journal.pone.0164660.g002
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mouse Jag1-Fc or another Notch ligand relevant in cancer, mouse Dll1-Fc [35,36] in PC3 cells.
Again, both Notch ligands induced PlexinD1 expression (S5C Fig), as well as PlexinD1 pro-
moter activity (S5D Fig), although to a lower extent compared to constitutive ligand-indepen-
dent receptor activation.
Notch and PlexinD1 signaling controls prostate cancer cell migration
A number of studies have reported that upregulated Notch signaling is associated with invasion
and metastasis in prostate cancer [37,38]. Notably, PlexinD1 levels are similarly regulated in
human prostate tumors and this signaling cascade controls prostate cancer cell behavior [8];
however, the underlyingmolecularmechanisms were not elucidated. In order to assess the
functional relevance of Notch-PlexinD1 signaling axis in prostate cancer cells, we performed
wound healing and Boyden chamber transwell migration assays with PC3 and DU145 prostate
cancer cells. We tested the effect of gamma secretase inhibitors blocking pan-Notch signaling
on PC3 migration, and consistent with previous data on DAPT treatment [29] we observed a
significant reduction of migratory ability (Fig 4A). Then, we observed that both Notch1 and
PlexinD1 silencing by shRNAs led to decreasedmigration in wound healing assays (Fig 4B and
4C). Moreover, knocking down either Notch1 or PlexinD1 similarly decreased the migration of
PC3 and DU145 prostate cancer cells in transwell migration assays (Fig 4D and S6A and S6B
Fig). The role of PlexinD1 signaling in the regulation of cell migration was further validated
upon gene knock down with two independent shRNA sequences (S6C and S6D Fig), as well as
by functional rescue upon re-expressing PlexinD1 in silenced cells by means of ectopic cDNA
transfection (S6E and S6F Fig). These data are consistent with the notion that these cancer cells
express endogenous Notch and PlexinD1 ligands, empowering basal autocrine signaling cir-
cuits [8,39].
Indeed, the overexpression of Notch ligands Dll1-Fc and Jag1-Fc in PC3 cells led to signifi-
cant induction of cell migration (Fig 4E). Moreover, similar results were observed in cells with
an enhanced autocrine circuit of the PlexinD1-ligand Sema3E-p61 (Fig 4F), and conversely we
observeddecreasedmigration of PC3 cells depleted of endogenous Sema3E (Fig 4G). Alto-
gether these experiments indicate that both Notch and PlexinD1 signaling cascades play
matching roles in regulating cell migration, consistent with Notch activity upregulating
Fig 3. Downregulation of Notch signaling inhibits PlexinD1 expression. (A) PC3 stably expressing shNotch1 or scrambled shRNA (shScr) as
control were generated, and protein lysates were analyzed by immunoblotting to reveal PlexinD1, Notch1 (intracellular domain, at 110 kDa) and
vinculin levels. (B) As above, PlexinD1, Notch1-ICD and vinculin levels were analyzed by immunoblotting in DU145 stably expressing shScr or
shNotch1, as in (A). (C, D) PC3 and DU145 cells transfected with PLXND1 promoter reporter construct (as in Fig 2) were treated with Notch inhibitors
DAPT (25μM) and RO4929097 (25μM) for 72 hrs, and Gaussia luciferase activity was assessed to reveal PLXND1 promoter regulation.
doi:10.1371/journal.pone.0164660.g003
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PlexinD1 expression in prostate cancer cells. Yet, the molecularmechanisms by which
Sema3E-PlexinD1 signaling could induce the migration of prostate cancer cells are presently
unknown.
Notch and PlexinD1 coordinately regulate gene expression in prostate
cancer cells
Notch signaling has been associated with the activation of transcription factors involved in the
so-called epithelial-mesenchymal transition (EMT), which promotes cell migration in develop-
ment, as well as cancer invasion and metastasis [19,40,41,42,43]. Thus, in order to identify the
protein mediators downstream to PlexinD1, we analyzed the expression of EMT transcription
factors Snail, Slug, Twist, Zeb1 and Zeb2 in PC3 prostate cancer cells. Interestingly, Slug levels
were consistently upregulated upon expression of activated Notch1, Notch3 or direct PlexinD1
overexpression (Fig 5A). In addition, both Notch ligand Jag1 and PlexinD1 ligand Sema3E-p61
significantly upregulated Slug levels (Fig 5B); conversely, Slug expression was reduced in cells
subjected to Notch1 or PlexinD1 silencing (Fig 5C). Interestingly, gene expression profiling of
human prostate cancer samples reported in TCGA database indicates significant correlation
between Slug expression and both Notch1 and PlexinD1 levels (S7A Fig); moreover, similar
results were obtained upon analyzing a distinct dataset (S7B Fig).
Fig 4. Notch and PlexinD1 signaling regulate prostate cancer cell migration. (A) Wound healing assay
in PC3 cells treated with gamma secretase inhibitors—DAPT and RO4929097 (as in Fig 3C). Wound closure
(24 hours from scratch) was quantified relative to wound width at start time. (B, C) The migration of PC3 cells
stably expressing shScr, shNotch1, shPlexinD1 was analyzed in wound healing assays, as above. Panel B
shows the quantification of wound sizes at the end of the experiment. (D) The migration of PC3 cells stably
expressing shScr, shPlexinD1 and shNotch1 was assayed in overnight Boyden chamber experiments with
transwell inserts. Bar graphs indicate mean values ± SD (normalized to controls). (E) PC3 cells
overexpressing Dll1-Fc and Jag1-Fc were analyzed in Boyden chamber experiment, as above. (F) PC3 cells
transduced to express an autocrine p61-Sema3E circuit were analyzed in Boyden chamber experiments, as
above. (G) PC3 cells stably expressing shSema3E compared to shScr were analyzed in Boyden chamber
experiments, as above. Mean ± SD is shown in all graphs; values were normalized to respective controls.
doi:10.1371/journal.pone.0164660.g004
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Fig 5. Notch1, Notch3 and PlexinD1 regulate EMT markers in prostate cancer cells. (A) PC3 were transiently transfected with GFP, N1-ICD,
N3-ICD or PlexinD1, and the mRNA levels of Snail, Slug, Zeb1, Zeb2, Twist1 were analyzed by qPCR (48 hours later). (B) PC3 cells were transfected
with GFP, Jag1-Fc, or Sema3E-p61; Slug mRNA levels were analyzed, as above. (C) Slug mRNA levels were assessed in PC3 cells stably
expressing pLKO or silenced for Notch1 and PlexinD1. (D) PC3 transiently transfected with pLKO, N1-ICD and PlexinD1 were analyzed for E-
cadherin mRNA levels by qPCR. (E) PC3 cells were transiently transfected with GFP, N1-ICD or N3-ICD; after 48 hrs lysates were analyzed by
immunoblotting to reveal E-cadherin levels. (F, G) PC3 and DU145 cells transfected with PlexinD1 were analyzed by immunoblotting to reveal E-
cadherin levels. (H, I) PC3 and DU145 cells, respectively, stably expressing shScr, shPlexinD1 and shNotch1 were analyzed by immunoblotting to
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E-cadherin downregulation is a hallmark associated with the activity of various transcrip-
tion factors driving the EMT program, including Slug. Indeed, reduced E-cadherin levels are
strongly linked to a gain of metastatic ability of prostate cancer cells to secondary sites [44,45].
Notably, overexpression of Notch1, Notch3, or PlexinD1 downregulated E-cadherin levels in
prostate cancer cells (Fig 5D, 5E, 5F and 5G). Conversely, cells knocked down for PlexinD1,
Sema3E or Notch1 expression, or treated with gamma secretase inhibitors of Notch signaling,
underwent E-cadherin upregulation (Fig 5H, 5I and 5L).
The specific requirement for Sema3E/PlexinD1 signaling to regulate E-cadherin levels was
further indicated by the functional rescue upon re-expression of a (non RNAi-sensitive) active
form of the ligand p61-Sema3E (Fig 5M). Moreover, similar results were obtained by transfect-
ing PlexinD1 cDNA in gene silenced cells (S8A Fig). Interestingly, a point mutant of PlexinD1
known to lack GAP activity (RA-mutant; [4] was still fully competent to mediate E-cadherin
downregulation (S8B Fig), consistent with the idea that PlexinD1 can mediate multiple signal-
ing cascades in cancer cells [46]. Furthermore, we found that E-cadherin upregulation in can-
cer cells subjected to PlexinD1 knock down was maintained upon transplantation in mice and
tumor formation in vivo (S9A and S9B Fig).
In further experiments we confirmed the relevant role of Slug to mediate Sema3E-induced
E-cadherin downregulation (Fig 5N) and increased cancer cell migration (Fig 5O). Notably, it
was previously reported that the nuclear translocation of another transcription factor (Snail)
induced by Sema3E in ovarian cancer cells was mediated by the PI3K/AKT pathway [6]. Thus
we tested whether inhibitors of intracellular signaling effectors PI3K andMAPK could interfere
with Sema3E/PlexinD1dependent upregulation of Slug levels in prostate cancer cells. Intrigu-
ingly, while we could not detect any change in presence of 10μM LY294002 PI3K inhibitor
(not shown), PlexinD1-dependent Slug upregulation (and consequent E-cadherin suppression)
was blunted upon treatment with the MAPK inhibitor PD98059 (10μM) (Fig 5P).
Taken together, these data indicate that both Notch and PlexinD1 signaling can upregulate
Slug expression in prostate cancer cells and concomitantly downregulate E-cadherin expres-
sion. In keeping with its role as transcriptional target of Notch, PlexinD1 could therefore also
be envisaged as relevant effector of Notch signaling cascade.
PlexinD1 acts downstream to Notch signaling to empower cancer cell
migration
As discussed above, transcriptional programs downstream to Notch signaling are known to
foster cancer cell migration/invasion [47,48,49]. Indeed, our data indicate that N1-ICD con-
comitantly promoted prostate cancer cells migration and downregulated E-cadherin levels. As
this also correlated with increased PlexinD1 expression, we asked whether PlexinD1 could be
the driver eliciting downstream regulatorymechanisms and cell migration. Thereby we trans-
fected constitutively active Notch in cells carrying PlexinD1-targeted shRNAs; in this setting,
PlexinD1 levels could not be induced by N1-ICD. Importantly, this prevented E-cadherin
downregulation and a gain of cancer cell migration in response to constitutive Notch signaling
reveal E-cadherin levels. (J) PC3 cells were treated with DMSO, DAPT (25μM) or RO4929097 (25μM) for 72 hrs and protein lysates were analyzed to
reveal E-cadherin levels. (K, L) PC3 cells stably expressing shScr or shSema3E were analyzed by western blotting (K) or qPCR (L) to reveal E-
cadherin levels. (M) Analysis of E cadherin levels by immunoblotting in PC3 cells stably silenced for Sema3E, and upon re-expression of Sema3E-
p61 (S3E-p61). (N) E cadherin and Slug expression levels assessed by qPCR upon overexpression of Sema3E-p61 in control and Slug-depleted cells
(by siRNA). (O) The migration of PC3 cells treated as in previous panels was assessed in Boyden Chamber assays. (P) Immunoblotting analysis of E
cadherin levels in PC3 cells transfected to overexpress PlexinD1 (or mock), with or without treatment with MAPK inhibitor PD98059 (10μM). Bar
graphs display mean values ± SD.
doi:10.1371/journal.pone.0164660.g005
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(Fig 6A and 6B). These data strongly suggest that PlexinD1 is required to mediate Notch activ-
ity in controlling cell migration.
We also performed the complementary experiment: since Notch1 silencing caused reduced
migration of PC3 and DU145 cells, correlating with lower PlexinD1 levels, we asked whether
the forced expression of PlexinD1 could restore, at least in part, this functional loss. As shown
in Fig 6C and 6D, PlexinD1 overexpression was able to downregulate E-cadherin levels inde-
pendent of Notch, and fully rescuedmigration defect (and E-cadherin loss) associated with
reduced Notch1 activity, consistent with the idea that PlexinD1 is located downstream of
Notch in the signaling cascade leading to E-cadherin regulation and increased cell migration.
Importantly, this effect was also appreciable in in vivo setting, where PlexinD1 overexpression
promoted metastatic cancer cell extravasation independently of Notch1 (Fig 6E and 6F).
Discussion
Previous studies have shown that Sema3E-PlexinD1 signaling is deregulated in human cancers;
however, the molecularmechanisms responsible for PlexinD1 overexpression remained unde-
termined. According to our findings, canonical Notch signaling is a positive regulator of Plex-
inD1 expression in an RBPjk dependent manner. This is supported by experimental evidence
in a range of cells of different tumor origin, either subjected to Notch1 genetic silencing or
treated with gamma secretase inhibitors to block this signaling cascade. Furthermore, we dem-
onstrated the positive regulatory activity of Notch signaling on PLXND1 promoter, dependent
on the canonical RBPJ-kappa pathway. Moreover, our data suggest that Notch1 and Notch3
may act redundantly in PlexinD1 regulation. Notably, Notch signaling is known to be upregu-
lated during progression of colon, breast, ovarian and prostate cancers [16,50,51]. Indepen-
dently, it was shown that PlexinD1 is overexpressed in the same tumor types [5,6,7,8]. Indeed,
by TCGA data mining we found a positive correlation of NOTCH1 and NOTCH3 expression
with PLXND1, supporting our hypothesis. In apparent conflict with this, a negative crosstalk
has been observed in retinal vessel development where Notch signaling was found to downre-
gulate PlexinD1[11]. However, PlexinD1 downregulation in zebrafish Notch signalingmutants
has also been reported [52], which supports our data in human cells.
The functional role of PlexinD1 signaling in cancer cell migration is under investigation.
For instance, Sema3E revealed dual regulatory activity on migration. A recombinant molecule
corresponding to the precursor full-length Sema3Emay display inhibitory function [8,53].
However, cancer cells often carry an autocrine loop of proteolytically processed isoform of
Sema3E (dubbed p61-Sema3E) which instead promotes cancer cell migration in PlexinD1-de-
pendent manner [5]. Indeed, here we show that p61-Sema3E signaling enhanced prostate can-
cer cells migration, while knocking down the endogenous Sema3E or PlexinD1 levels inhibited
it. Previous work has reported that PlexinD1 can functionally interact with ErbB2 and elicit
invasion and metastasis [5]. However, we found that this mechanism is unlikely to have a role
in PC3 prostate cancer cells, as they express low levels of ErbB2 and the treatment with the
kinase inhibitor lapatinib didn’t seem to interfere with Sema3E/PlexinD1-mediated effects (M.
R., unpublished results). In ovarian cancer cells it was reported that Sema3E signaling drives
nuclear translocation of Snail, a transcription factor controlling E-cadherin expression. Our
work now demonstrates that PlexinD1 regulates E-cadherin levels and cell migration in pros-
tate cancer cells. Intriguingly, we could not detect any significant change of subcellular Snail
localization upon N1-ICD or PlexinD1 overexpression in prostate cancer cells (data not
shown), but we observed significant induction in the expression of Slug, another transcription
factor known to drive E-cadherin loss. Notably, Slug was recently reported to be required for
EMT and invasiveness of breast cancer cells in response to Notch signaling [49]. Thus, based
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Fig 6. PlexinD1 acts downstream of Notch signaling in down-regulating E-cadherin and promoting
cancer cell migration. (A, B) PC3 cells were transiently transfected with either shScr, N1-ICD, shPlexinD1,
or a combination of N1-ICD and shPlexinD1. 72 hrs after transfection, cell migration was analysed by Boyden
chamber assays (A). Moreover, cell lysates were analyzed by immunoblotting to reveal E-cadherin,
Notch1-ICD and vinculin levels (B); relative E-cadherin band intensity to vinculin levels was quantified and
normalized to controls. (C, D) PC3 cells were transiently transfected with either shScr, shNotch1, PlexinD1,
or a combination of shNotch1 and PlexinD1. 72 hrs after transfection, cell migration was analysed by Boyden
chamber assays (C). Moreover, cell lysates were analyzed by immunoblotting to reveal E-cadherin, N1-ICD,
PlexinD1 and vinculin levels (D) and relative E-cadherin band intensity to vinculin levels was quantified and
normalized to controls. (E, F) PC3 cells transfected as in C-D were analyzed in vivo by metastatic
extravasation assay upon tail vein injection in mice. Representative images are shown (E) along with
fluorescence intensity quantification (F). Bar graphs show mean values ± SD (normalized to control).
doi:10.1371/journal.pone.0164660.g006
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on our findings, we propose that in prostate cancer cells PlexinD1mediates Slug upregulation
elicited by Notch signaling. Interestingly, the molecularmechanisms linking Sema3E/PlexinD1
to Slug upregulation seem to be distinct from downstream pathways reported so far, and puta-
tively implicate MAPK activity; further studies are warranted to elucidate this novel signaling
cascade.
Conclusion
In this study we have shown for the first time that Notch signaling (both Notch1 and Notch3
receptors) upregulates PlexinD1 expression at the promoter level in different cells. This regula-
torymechanism is dependent on canonical Notch signaling, as RBPjk itself can induce Plex-
inD1 expression, while this is blocked by its dominant negative form. Notch1 and Notch3
expression is positively correlated with that of PlexinD1 in patient cancer samples. We have
revealed that PlexinD1 expression is required to mediate cancer cell migration induced by con-
stitutive Notch signaling in prostate cancer cells; moreover, PlexinD1 expression is sufficient to
promote cancer cell migration downstream of Notch. Notably, the overexpression of Notch1,
Notch3 and PlexinD1 induces Slug transcription factor and downregulates E-cadherin levels in
prostate cancer cells, a phenotype associated with increased cell migration and metastatic
potential in vivo. This signaling cascademight be important in the gain of invasive and meta-
static ability of human prostate tumors, and its therapeutic targeting could be envisaged by
treatment with Notch signaling inhibitors.
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S1 Fig. Notch signaling regulates PlexinD1 expression in cancer and normal cells. (A, B)
Constitutively active Notch1-intracellular domain (N1-ICD) was overexpressed in glioblas-
toma-derived cell lines U87 and U251, and PlexinD1 protein expression was determined in cell
lysates by immunoblotting. Vinculin levels were analyzed to provide reference for protein load-
ing. (C) PlexinD1 protein detection by immunoblotting in HUVEC cells overexpressing
N1-ICD. (D) GEO dataset GSE40403 was analyzed for expression ofHES1,HEY1 and
PLXND1 in HUVEC cells overexpressing Notch ligand Jag1 (D) or subjected to NOTCH1
knock-down (E).
(PDF)
S2 Fig. Correlation of mRNA expression of Notch1/Notch3 and PlexinD1 in different
human cancers. (A-B) TCGA datasets of prostate, colon and rectum adenocarcinoma, thyroid
and kidney renal cell carcinoma were analyzed using cBioportal interface for Notch1 (or
Notch3, respectively) and PlexinD1 expression levels; two-gene correlations were plotted, also
indicating Spearman correlation coefficients (r). p value was calculated from the panel of
‘mutual exclusivity and co-occurrence analysis’. (C) 293T cells were transiently transfected
with mock plasmid, N1-ICD or N3-ICD in combination with Hes1 Luc reporter plasmid. 48
hrs after transfection, cells were lysed and Hes1-luc reporter activity was measured.Mean
values ± SD are shown. (D) COS7 cells were transfected with 12X CBF dsRed reporter in com-
bination with mock plasmid, N1-ICD and N3-ICD. Mean ± SD is shown.
(PDF)
S3 Fig. Notch signaling specificallysustains PlexinD1 expression. (A) PlexinD1mRNA lev-
els were analyzed in KM20, PC3, A549, COLO741, MDA435 cancer cells stably expressing
shNotch1 or shScr. Relative gene expression was normalized to control cells. (B) PlexinB1
mRNA levels were analyzed by qPCR in the indicated tumor cells expressing shNotch1 (or
shScr). (C) Three independent shRNAs targeting Notch1 were transfected in PC3 cells to
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validate the specific effect of this knock down on PlexinD1mRNA levels. Bar graphs show
mean values ± SD.
(PDF)
S4 Fig. Notch signaling inhibition downregulatesPlexinD1 levels. (A) The presence of acti-
vated Notch1 intracellular cleaved domain (N1-ICD) in 293T and PC3 cells was revealed by
immunoblotting with an isoform specific anti-Val1744 antibody;N1-ICD levels dramatically
dropped in cells treated with (γ-secretase)Notch cleavage inhibitors DAPT (25μM) or
RO4929097 (25μM). (B) The mRNA levels of Notch target genesHES1 and PLXND1were ana-
lyzed by qPCR in HUVEC endothelial cells, in basal conditions and upon treatment with
Notch inhibitors DAPT or RO4929097. (C-D) PC3 cells were treated with DAPT (25μM) and
RO4929097 (25μM) for 72 hrs and PLXND1mRNA were analyzed by qPCR (C); indepen-
dently, protein lysates were analyzed for PlexinD1 and vinculin by immunoblotting (D). (E)
MCF7 and KM20 carcinoma cells were treated with Notch inhibitors DAPT or RO4929097 for
72 hrs (in independent experiments), and cell lysates were analyzed by immunoblotting to
reveal PlexinD1 expression levels.
(PDF)
S5 Fig. Regulation of PlexinD1 expression by Notch ligands. (A) PC3 cells were treated with
7.5 μM Jag1 soluble peptide for 24hrs and compared with untreated control cells. PlexinD1
and Hes1 mRNA levels were analyzed by qPCR. (B) PC3 cells were transfected with PlexinD1
promoter reporter construct (as in main Fig 2); the following day the cells were treated with
Jag1 peptide 7.5 μM or Jag1 peptide plus Notch inhibitor RO4929097 (25μM), and after 24hrs
cell-conditionedmedia were analyzed to revealGaussia luciferase activity. (C) PC3 cells were
transiently transfectedwith either GFP, Dll1-Fc or Jag1-Fc; 48 hours later, PlexinD1 and vincu-
lin levels were analyzed by immunoblotting; relative band intensity was quantified and normal-
ized to controls. (D) PC3 cells were transfected with PlexinD1 promoter reporter construct in
combination with Dll1-Fc, Jag1-Fc and N1-ICD. Mean ± SD is shown.
(PDF)
S6 Fig. DU145 and PC3 cell migration is regulated by Notch and PlexinD1 signaling. (A)
Analysis of DU145 prostate cancer cells migration (in transwell Boyden Chamber assays) upon
treatment with Notch inhibitors DAPT and RO4929097. (B) DU145 cells migration was simi-
larly scored in cells stably expressing shPlexinD1, shNotch1 or shScr. Mean ± SD is shown.
(C-D) PlexinD1 expression in PC3 cells was knocked-downby stable expression of two inde-
pendent shRNA constructs, indicated as #48 and #52 (C; seeMethods), and the migration of
these cells was assessed by Boyden chamber assay (D). (E-F) Boyden chamber migration assays
with PC3 cells subjected to PlexinD1 knock-down by siRNAs (directed against 3’ untranslated
sequence) and subsequently transfected with non-targetable PlexinD1 cDNA construct to
achieve re-expression (and relative control conditions); representative images (E) and quantita-
tive analysis (F). Mean ± SD is shown.
(PDF)
S7 Fig. Correlation of Slug expression with PlexinD1 and Notch1 in human prostate can-
cer. (A) Correlation analysis of mRNA levels of Slug (SNAI2 gene symbol) and either Notch1
or PlexinD1 in TCGA prostate cancer dataset (n = 499). Spearman coefficient and p values are
indicated in the graph. (B) Correlation of Slug and PlexinD1mRNA levels in GEO—GSE54460
prostate cancer dataset (n = 106). Differential gene expression is indicated as Log2 values on
either axis.
(PDF)
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S8 Fig. Regulation of E cadherin levels by PlexinD1 signaling. (A) E-cadherin expression lev-
els were analyzed by immunoblotting in PC3 cells subjected to PlexinD1 knock-down by siR-
NAs and/or subsequently transfected with non-targetable PlexinD1 cDNA construct to achieve
re-expression (same conditions as analyzed in Fig 6E and 6F). (B) Functional rescue experi-
ment similar to that in A, by re-expressing wild-type or RA-mutated PlexinD1 constructs in
gene silenced cells (by siRNAs); PlexinD1 and E cadherin levels were revealed by immunoblot-
ting.
(PDF)
S9 Fig. Regulation of E cadherin levels by PlexinD1 in vitro and in tumor xenografts in
vivo. (A) Q-PCR analysis of E cadherinmRNA levels in PC3 cells stably expressing shPlex-
inD1. (B) IHC analysis of E cadherin expression in tumor xenografts formed by the same cells
analyzed in A.
(PDF)
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